|
ABOUT COMPANY
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
|
EARNINGS
Gross Profit (TTM): 6169000
Market Capitalization: 431542000
Operating Margin (TTM): -1.179
PE Ratio: None
PEG Ratio: -0.17
Profit Margin: -1.366
Revenue Per Share (TTM): 1.457
Revenue (TTM): 90521000
Quarterly Earnings Growth YOY: 0
Quarterly Revenue Growth YOY: 0.149
Trailing PE: -
|
DIVIDENDS
Diluted EPS (TTM): -1.994
Dividend Date: None
Dividend Per Share: None
Dividend Yield: 0%
EBITDA: -81135000
ExDividend Date: None
Forward Annual Dividend Rate:
Forward Annual Dividend Yield:
|